Helicobacter pylori associated gastritis
Conditions
Interventions
A:Rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg and colloidal bismuth pectin 200 mg, all twice daily for 14 days
B:After the use of rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg and colloidal bismuth pectin 200 mg, all twice daily for 14 days, take Sucralfate Suspensoid Gel twice a day for 14 day
Sponsors
Shandong Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Adult patients, aged 18-60 years; 2. The patients who did not take antibiotics, bismuth and traditional Chinese medicine in 4 weeks before treatment did not take PPI, H2 receptor antagonist and other drugs in 2 weeks; 3. Patients diagnosed as HP positive by C13 or C14 urea breath test and rapid urease test; 4. The patients who knew and agreed to participate in this study had complete medical records and follow-up records; 5. Patients without any Helicobacter pylori eradication treatment within half a year.
Exclusion criteria
Exclusion criteria: 1. Patients with history of diabetes, hypertension and kidney disease; 2. Patients with digestive tract obstruction; 3. Patients with severe heart, lung and liver dysfunction; 4. Patients with hypophosphatemia; 5. Patients with malignant tumor; 6. Patients who have received hemodialysis treatment; 7. Patients who had received parenteral nutrition treatment; 8. Pregnant or lactating women or women of childbearing age without effective contraceptive measures; 9. Patients allergic to sucralfate or drugs in this study; 10. Patients who need to take tetracyclines during the study period; 11. Patients with mental illness; 12. Subjects unable to complete the test according to the test requirements; 13. Subjects without legal capacity or insight; 14. Subjects who participated in any drug clinical trial three months before entering the study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Relief rate of digestive tract symptoms;The incidence of adverse reactions (including bitter mouth, taste disorder, black tongue coating, nausea, diarrhea, anorexia, gray-black stool, etc.); | — |
Primary
| Measure | Time frame |
|---|---|
| Assessment of mucosal damage;Hp eradication rate after treatment; | — |
Countries
China
Contacts
Public ContactZhang Chunqing
Shandong Provincial Hospital
Outcome results
None listed